Sangamo BioSciences, Inc. is a clinical-stage biotechnology company focused on the research, development, and commercialization of engineered DNA-binding proteins (e.g., zinc finger proteins, or ZFPs) for therapeutic genome editing and gene regulation. The company's proprietary ZFP technology platform enables specific and precise targeting of genes and genetic regulatory elements to achieve therapeutic outcomes. Sangamo's lead product candidate, SB-913, is being developed for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, and SB-318 is being developed for the treatment of MPS I. The company is also developing gene therapies for hemophilia A and B, beta-thalassemia, and sickle cell disease. Sangamo has collaborations with several pharmaceutical companies, including Pfizer, Sanofi, and Kite Pharma, a subsidiary of Gilead Sciences.